|By Marketwired .||
|July 8, 2014 05:10 PM EDT||
MINNEAPOLIS, MINNESOTA -- (Marketwired) -- 07/08/14 -- DiaMedica Inc. (TSX VENTURE:DMA), a clinical stage biopharmaceutical company focused on the treatment of diabetes and its complications, today announced a grant of 150,000 stock options to Richard Pilnik, the Company's newly appointed Chairman of the Board. The options were awarded in accordance with the Stock Option Plan at an exercise price of CAD $0.69 and a term of 10 years. The options are subject to acceptance by the TSX Venture Exchange.
DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage biopharmaceutical company focused on the discovery and development of novel therapies to treat diabetes and the complications associated with diabetes. DiaMedica's lead clinical stage product, DM199, is a recombinant human protein known as rhKLK1 that represents a novel approach to treating diabetes and associated complications. DiaMedica is also developing a novel monoclonal antibody, DM204 for the treatment of Type 2 diabetes, which is in preclinical development.
The Company is listed on the TSX Venture Exchange in Canada under the trading symbol 'DMA'.
The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address DiaMedica's expectations, including the intended use of the net proceeds of the Offering, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in DiaMedica's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. DiaMedica undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events, unless required by law. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the contents of this press release.
Chief Financial Officer
Jan. 20, 2017 12:45 AM EST Reads: 2,865
Jan. 20, 2017 12:45 AM EST Reads: 4,103
Jan. 20, 2017 12:45 AM EST Reads: 2,811
Jan. 20, 2017 12:00 AM EST Reads: 6,328
Jan. 19, 2017 11:45 PM EST Reads: 9,913
Jan. 19, 2017 09:45 PM EST Reads: 6,815
Jan. 19, 2017 09:45 PM EST Reads: 7,696
Jan. 19, 2017 09:00 PM EST Reads: 4,556
Jan. 19, 2017 08:45 PM EST Reads: 5,387
Jan. 19, 2017 07:30 PM EST Reads: 4,237
Jan. 19, 2017 05:30 PM EST Reads: 3,643
Jan. 19, 2017 05:15 PM EST Reads: 3,113
Jan. 19, 2017 05:15 PM EST Reads: 1,343
Jan. 19, 2017 04:45 PM EST Reads: 3,771
Jan. 19, 2017 04:45 PM EST Reads: 3,492